

Joan Tymon-Rosario

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6687704/publications.pdf>

Version: 2024-02-01

35
papers

320
citations

1040056

9
h-index

940533

16
g-index

35
all docs

35
docs citations

35
times ranked

315
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100913.	0.6	2
2	An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	6
3	Minimally Invasive Ovarian-Preserving Approach for the Management of a Sclerosing Stromal Tumor in an Adolescent: A Case Report. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2022, 35, 505-508.	0.7	4
4	Immune checkpoint inhibitors for recurrent endometrial cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 249-258.	2.4	7
5	Robotic interval debulking with radical hysterectomy and partial urinary bladder resection for locally advanced carcinosarcoma of the uterus. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100959.	0.6	0
6	Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 633-645.	2.4	8
7	Robotic Low Anterior Resection and Partial Bladder Resection for Management of Locoregional Endometrial Cancer Recurrence. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 176-177.	0.6	0
8	Financial toxicity in patients with gynecologic malignancies: a cross sectional study. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e87.	2.2	10
9	Benefits of a Multidisciplinary Women's Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 143-149.	1.3	4
10	Immunotherapy in Cervical Cancer. <i>Current Oncology Reports</i> , 2021, 23, 61.	4.0	41
11	Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. <i>Gynecologic Oncology</i> , 2021, 163, 93-99.	1.4	14
12	Variability in the identification of lymphovascular space invasion for early stage cervical cancer. <i>Surgical Oncology</i> , 2021, 38, 101566.	1.6	4
13	Novel antibody-drug conjugates: current and future roles in gynecologic oncology. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 26-33.	2.0	1
14	Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment. <i>Cancers</i> , 2021, 13, 6239.	3.7	13
15	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020, 14, 645-656.	4.6	20
16	In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 430-438.	1.4	18
17	Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. <i>Gynecologic Oncology</i> , 2020, 159, 17-22.	1.4	42
18	Robotic radical trachelectomy with an abdominally placed vaginal cerclage for containment of early stage cervical cancer. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100673.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 118.	2.8	30
20	Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. <i>Gynecologic Oncology</i> , 2020, 158, 769-775.	1.4	2
21	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. <i>Scientific Reports</i> , 2020, 10, 973.	3.3	31
22	Sacituzumab govitecan: A promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer. <i>Oncoscience</i> , 2020, 7, 68-69.	2.2	3
23	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570.	1.8	32
24	Streptococcus constellatus Peritonitis and Subsequent Septic Shock following Intrauterine Device Removal. <i>Case Reports in Obstetrics and Gynecology</i> , 2019, 2019, 1-5.	0.3	2
25	Multidrug-Resistant <i>Escherichia coli</i> Resulting in Postpartum Necrotizing Endomyometritis. <i>Case Reports in Obstetrics and Gynecology</i> , 2019, 2019, 1-3.	0.3	3
26	Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S308-S308.	1.7	0
27	Racial Differences in Survival From Epithelial Ovarian Cancer Are Associated With Stage at Diagnosis and Use of Neoadjuvant Therapy: A 10-Year Single-Institution Experience With a Racially Diverse Urban Population. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 749-756.	2.5	5
28	Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1318-1324.	2.5	4
29	Selective Reduction of a Heterotopic Cesarean Scar Pregnancy Complicated by Septic Abortion. <i>Case Reports in Obstetrics and Gynecology</i> , 2018, 2018, 1-4.	0.3	5
30	Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 134-140.	1.4	1
31	Association of diabetes mellitus with an increased risk of recurrence and disease progression in women with ovarian granulosa cell tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, e17521-e17521.	1.6	1
32	Association of unplanned hospitalizations after chemotherapy with disease specific survival in a racially ethnically diverse population of women with epithelial ovarian cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, e17517-e17517.	1.6	0
33	Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population. <i>Gynecologic Oncology</i> , 2017, 147, 36-40.	1.4	7
34	Survival disparity and racial differences in the use of neoadjuvant chemotherapy (NAC) compared with primary debulking surgery (PDS) in women with ovarian cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, e17099-e17099.	1.6	0
35	A retrospective evaluation of unplanned hospital admission rates for women with ovarian cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, e18129-e18129.	1.6	0